Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10121709 | 0.91 | HCRTR2 (0.57) | HCRTR2HCRTR1 | |
| SCHEMBL609530 | 0.90 | HCRTR1 (0.53) | HCRTR2HCRTR1 | |
| SCHEMBL610625 | 0.87 | HCRTR2 (0.61) | HCRTR2HCRTR1 | |
| SCHEMBL609123 | 0.86 | HCRTR2 (0.55) | HCRTR2HCRTR1 | |
| SCHEMBL610684 | 0.86 | HCRTR2 (0.55) | HCRTR2HCRTR1 | |
| SCHEMBL609784 | 0.85 | HCRTR2 (0.55) | HCRTR2HCRTR1 | |
| SCHEMBL609512 | 0.85 | HCRTR2 (0.54) | HCRTR2HCRTR1 | |
| SCHEMBL609971 | 0.85 | HCRTR1 (0.53) | HCRTR2HCRTR1 | |
| SCHEMBL609028 | 0.85 | HCRTR2 (0.57) | HCRTR2HCRTR1 | |
| SCHEMBL611464 | 0.84 | HCRTR1 (0.54) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | claimed |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR2 1/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.